Sinopharm Dongfeng General Hospital, Hubei University of Medicine, Hubei Key Laboratory of Wudang Local Chinese Medicine Research (Hubei University of Medicine), Shiyan, China.
Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China.
Front Immunol. 2022 Dec 8;13:997578. doi: 10.3389/fimmu.2022.997578. eCollection 2022.
Glucagon-like peptide-1 (GLP-1) is a 30-amino acid hormone secreted by L cells in the distal ileum, colon, and pancreatic α cells, which participates in blood sugar regulation by promoting insulin release, reducing glucagon levels, delaying gastric emptying, increasing satiety, and reducing appetite. GLP-1 specifically binds to the glucagon-like peptide-1 receptor (GLP-1R) in the body, directly stimulating the secretion of insulin by pancreatic β-cells, promoting proliferation and differentiation, and inhibiting cell apoptosis, thereby exerting a glycemic lowering effect. The glycemic regulating effect of GLP-1 and its analogues has been well studied in human and murine models in the circumstance of many diseases. Recent studies found that GLP-1 is able to modulate innate immune response in a number of inflammatory diseases. In the present review, we summarize the research progression of GLP-1 and its analogues in immunomodulation and related signal pathways.
胰高血糖素样肽-1(GLP-1)是一种由回肠远端、结肠和胰腺α细胞分泌的 30 个氨基酸激素,通过促进胰岛素释放、降低胰高血糖素水平、延缓胃排空、增加饱腹感和减少食欲来参与血糖调节。GLP-1 特异性地与体内的胰高血糖素样肽-1 受体(GLP-1R)结合,直接刺激胰腺β细胞分泌胰岛素,促进增殖和分化,抑制细胞凋亡,从而发挥降血糖作用。在许多疾病的情况下,已经在人和鼠模型中对 GLP-1 及其类似物的血糖调节作用进行了很好的研究。最近的研究发现,GLP-1 能够调节多种炎症性疾病中的固有免疫反应。在本综述中,我们总结了 GLP-1 及其类似物在免疫调节及相关信号通路中的研究进展。